Selected article for: "high level and inflammasome activation"
Author: Al-kuraishy, Hayder M.; Al-Gareeb, Ali I.; Qusti, Safaa; Alshammari, Eida M.; Atanu, Francis O.; Batiha, Gaber El-Saber
Title: Arginine vasopressin and pathophysiology of COVID-19: An innovative perspective
  • Cord-id: xactiq7e
  • Document date: 2021_9_15
    • ID: xactiq7e
    Snippet: In Covid-19, systemic disturbances may progress due to development of cytokine storm and dysregulation of and plasma osmolarility due to high release of pro-inflammatory cytokines and neuro-hormonal disorders. Arginine vasopressin (AVP) which is involve in the regulation of body osmotic system, body water content, blood pressure and plasma volume, that are highly disturbed in Covid-19 and linked with poor clinical outcomes. Therefore, this present study aimed to find the potential association be
    Document: In Covid-19, systemic disturbances may progress due to development of cytokine storm and dysregulation of and plasma osmolarility due to high release of pro-inflammatory cytokines and neuro-hormonal disorders. Arginine vasopressin (AVP) which is involve in the regulation of body osmotic system, body water content, blood pressure and plasma volume, that are highly disturbed in Covid-19 and linked with poor clinical outcomes. Therefore, this present study aimed to find the potential association between AVP serum level and inflammatory disorders in Covid-19. It has been observed by different recent studies that physiological response due to fever, pain, hypovolemia, dehydration, and psychological stress is characterized by activation release of AVP to counter-balance high blood viscosity in Covid-19 patients. In addition, activated immune cells mainly T and B lymphocytes and released pro-inflammatory cytokines stimulate discharge of stored AVP from immune cells, which in a vicious cycle trigger release of pro-inflammatory cytokines. Vasopressin receptor antagonists have antiviral and anti-inflammatory effects that may inhibit AVP-induced hyponatremia and release of pro-inflammatory cytokines in Covid-19. In conclusion, release of AVP from hypothalamus is augmented in Covid-19 due to stress, high pro-inflammatory cytokines, high circulating AngII and inhibition of GABAergic neurons. In turn, high AVP level leads to induction of hyponatremia, inflammatory disorders, and development of complications in Covid-19 by activation of NF-κB and NLRP3 inflammasome with release of pro-inflammatory cytokines. Therefore, AVP antagonists might be novel potential therapeutic modality in treating Covid-19 through mitigation of AVP-mediated inflammatory disorders and hyponatremia.

    Search related documents:
    Co phrase search for related documents
    • acth adrenocorticotrophic hormone and adrenocorticotrophic hormone: 1, 2
    • activation release and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • activation release and acute pulmonary edema: 1
    • activation release and lung epithelial alveolar: 1, 2
    • activation release and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute ards respiratory distress syndrome and adrenocorticotrophic hormone: 1
    • acute ards respiratory distress syndrome and liver cirrhosis: 1, 2
    • acute ards respiratory distress syndrome and lung epithelial alveolar: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute ards respiratory distress syndrome and lung epithelial alveolar type ii: 1
    • acute ards respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
    • acute ards respiratory distress syndrome progression and lung epithelial alveolar: 1
    • acute ards respiratory distress syndrome progression and lung injury: 1, 2, 3, 4, 5, 6, 7
    • acute pneumonitis and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute pneumonitis lung injury and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10